Published in J Thromb Haemost on July 01, 2011
Human CalDAG-GEFI gene (RASGRP2) mutation affects platelet function and causes severe bleeding. J Exp Med (2014) 1.80
The VPS33B-binding protein VPS16B is required in megakaryocyte and platelet α-granule biogenesis. Blood (2012) 1.67
Glanzmann thrombasthenia: state of the art and future directions. Semin Thromb Hemost (2013) 1.08
TMEM16F (Anoctamin 6), an anion channel of delayed Ca(2+) activation. J Gen Physiol (2013) 1.08
Does size matter in platelet production? Blood (2012) 1.07
Identification of platelet function defects by multi-parameter assessment of thrombus formation. Nat Commun (2014) 1.03
Platelet secretion: From haemostasis to wound healing and beyond. Blood Rev (2014) 1.03
Defective release of α granule and lysosome contents from platelets in mouse Hermansky-Pudlak syndrome models. Blood (2014) 1.02
C560Rβ3 caused platelet integrin αII b β3 to bind fibrinogen continuously, but resulted in a severe bleeding syndrome and increased murine mortality. J Thromb Haemost (2013) 0.94
Of von Willebrand factor and platelets. Cell Mol Life Sci (2014) 0.93
Lessons from rare maladies: leukocyte adhesion deficiency syndromes. Curr Opin Hematol (2013) 0.92
Platelet biogenesis and functions require correct protein O-glycosylation. Proc Natl Acad Sci U S A (2012) 0.90
State of the art in platelet function testing. Transfus Med Hemother (2013) 0.90
Secrets of platelet exocytosis - what do we really know about platelet secretion mechanisms? Br J Haematol (2013) 0.90
Inherited platelet disorders: Insight from platelet genomics using next-generation sequencing. Platelets (2016) 0.87
Eryptosis as a marker of Parkinson's disease. Aging (Albany NY) (2014) 0.86
Polyphosphate suppresses complement via the terminal pathway. Blood (2013) 0.85
Determination of ATP and ADP Secretion from Human and Mouse Platelets by an HPLC Assay. Transfus Med Hemother (2013) 0.84
Correlation between platelet phenotype and NBEAL2 genotype in patients with congenital thrombocytopenia and α-granule deficiency. Haematologica (2012) 0.81
Genomic landscape of megakaryopoiesis and platelet function defects. Blood (2016) 0.81
Elucidation of the CHO Super-Ome (CHO-SO) by Proteoinformatics. J Proteome Res (2015) 0.78
Suppressive effect of CORM-2 on LPS-induced platelet activation by glycoprotein mediated HS1 phosphorylation interference. PLoS One (2013) 0.76
Structure and Ligand-Binding Mechanism of a Cysteinyl Leukotriene-Binding Protein from a Blood-Feeding Disease Vector. ACS Chem Biol (2016) 0.75
The Utility of Platelet and Coagulation Testing of Antithrombotics: Fusing Science with Patient Care. Drug Dev Res (2013) 0.75
A Potential Mechanism of High-Dose Ticagrelor in Modulating Platelet Activity and Atherosclerosis Mediated by Thymic Stromal Lymphopoietin Receptor. PLoS One (2015) 0.75
Prevalence of disease and relationships between laboratory phenotype and bleeding severity in platelet primary secretion defects. PLoS One (2013) 0.75
Platelet dense granules begin to selectively accumulate mepacrine during proplatelet formation. Blood Adv (2017) 0.75
Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature (2001) 5.51
Analysis of platelet membrane glycoprotein polymorphisms in Glanzmann thrombasthenia showed the French gypsy mutation in the alphaIIb gene to be strongly linked to the HPA-1b polymorphism in beta3. J Thromb Haemost (2003) 2.20
Induction of megakaryocytes to synthesize and store a releasable pool of human factor VIII. J Thromb Haemost (2003) 1.74
Use of recombinant factor VIIa in 3 patients with inherited type I Glanzmann's thrombasthenia undergoing invasive procedures. Thromb Haemost (2000) 1.71
Recommendations for the Standardization of Light Transmission Aggregometry: A Consensus of the Working Party from the Platelet Physiology Subcommittee of SSC/ISTH. J Thromb Haemost (2013) 1.25
Mean platelet volume: comparison of three analysers towards standardization of platelet morphological phenotype. Int J Lab Hematol (2012) 1.23
Clopidogrel: a review of its mechanism of action. Platelets (1998) 1.05
C560Rβ3 caused platelet integrin αII b β3 to bind fibrinogen continuously, but resulted in a severe bleeding syndrome and increased murine mortality. J Thromb Haemost (2013) 0.94
Ultrastructural studies of platelet aggregates from human subjects receiving clopidogrel and from a patient with an inherited defect of an ADP-dependent pathway of platelet activation. Arterioscler Thromb Vasc Biol (1996) 0.90
Natural history of platelet antibody formation against αIIbβ3 in a French cohort of Glanzmann thrombasthenia patients. Haemophilia (2012) 0.88
Ultrastructural analysis of the distribution of the vitronectin receptor (alpha v beta 3) in human platelets and megakaryocytes reveals an intracellular pool and labelling of the alpha-granule membrane. Br J Haematol (1997) 0.88
Anti-platelet antibodies in patients with systemic lupus erythematosus and the primary antiphospholipid antibody syndrome: their relationship with the observed thrombocytopenia. Br J Haematol (1997) 0.87
The cleaved peptide of PAR1 results in a redistribution of the platelet surface GPIb-IX-V complex to the surface-connected canalicular system. Thromb Haemost (2000) 0.84
Ultrastructural analysis of bone marrow hematopoiesis in mice transgenic for the thymidine kinase gene driven by the alpha IIb promoter. Blood (1998) 0.83
The abnormal proplatelet formation in MYH9-related macrothrombocytopenia results from an increased actomyosin contractility and is rescued by myosin IIA inhibition. J Thromb Haemost (2013) 0.83
A 2.7-kb portion of the 5' flanking region of the murine glycoprotein alphaIIb gene is transcriptionally active in primitive hematopoietic progenitor cells. Blood (1997) 0.83
Platelet glycoprotein IIb/IIIa inhibitors: basic and clinical aspects. Arterioscler Thromb Vasc Biol (1999) 0.83
Two different beta3 cysteine substitutions alter alphaIIb beta3 maturation and result in Glanzmann thrombasthenia. Thromb Haemost (2002) 0.83
Three cases of acquired von Willebrand disease associated with systemic lupus erythematosus. Br J Haematol (1999) 0.82
A review of the role of platelet membrane glycoproteins in the platelet-vessel wall interaction. Baillieres Clin Haematol (1993) 0.81
A case of profound and prolonged tirofiban-induced thrombocytopenia and its correction by intravenous immunoglobulin G. J Thromb Haemost (2007) 0.81
Inherited defects of platelet function. Rev Clin Exp Hematol (2001) 0.81
Rebuttal: the French Gypsy mutation does not give rise to a particularly mild form of Glazmann's thrombasthenia. J Thromb Haemost (2003) 0.80
Confirmation that GP Ib-IX complexes have a reduced surface distribution on platelets activated by thrombin and TRAP-14-mer peptide. Br J Haematol (1995) 0.78
Family screening for a Glanzmann's thrombasthenia mutation using PCR-SSCP. Platelets (1998) 0.78
Flow cytometry reveals activated GP IIb-IIIa complexes on platelets from patients undergoing thrombolytic therapy after acute myocardial infarction. Blood Coagul Fibrinolysis (1995) 0.78
Inhibition of platelet aggregation by abciximab but not by aspirin can be detected by a new point-of-care test, the hemostatus. Thromb Res (1999) 0.77
PAICA: a method for characterizing platelet-associated antibodies--its application to the study of idiopathic thrombocytopenic purpura and to the detection of platelet-bound c7E3. Thromb Haemost (1996) 0.77
Rare homozygous status of P43 β1-tubulin polymorphism causes alterations in platelet ultrastructure. Thromb Haemost (2011) 0.77
Markers of platelet activation in coronary heart disease patients. Eur J Clin Invest (1994) 0.77
Autoimmune thrombocytopenic purpura (AITP) and acquired thrombasthenia due to autoantibodies to GP IIb-IIIa in a patient with an unusual platelet membrane glycoprotein composition. Am J Hematol (1998) 0.77
Expression of markers of platelet activation and the interpatient variation in response to abciximab. Arterioscler Thromb Vasc Biol (1999) 0.76
Annexin V relocates to the periphery of activated platelets following thrombin activation: an ultrastructural immunohistochemical approach. Cell Biol Int (1999) 0.76
Ultrastructural analysis of megakaryocytes in GPV knockout mice. Thromb Haemost (2000) 0.76
Abciximab binding to glycoprotein IIb-IIa and protein tyrosine phosphorylation in human platelets. Blood (1999) 0.75
Altered megakaryocytopoiesis in von Willebrand type 2B disease. J Thromb Haemost (2009) 0.75
[Epidural labor analgesia and parturient with type 2B von Willebrand disease]. Ann Fr Anesth Reanim (2012) 0.75
Ultrastructural analysis of the distribution of von Willebrand factor and fibrinogen in platelet aggregates formed in the PFA-100. Platelets (1998) 0.75
Abnormal tyrosine phosphorylation linked to a defective interaction between ADP and its receptor on platelets. Thromb Haemost (1998) 0.75
Incidence of anti-mouse antibodies in thrombocytopenic patients with autoimmune disorders. Hum Antibodies (1997) 0.75
Autoantibodies and anti-mouse antibodies in thrombocytopenic patients as assessed by different MAIPA assays. Br J Haematol (1996) 0.75
A close spatial relationship between GP IIb-IIIa complexes and CD9 antigen as demonstrated by the MAIPA technique. Platelets (1996) 0.75
Visualization of activation-dependent epitopes on glycoprotein IIb-IIIa complexes of platelets stimulated by thrombin: immunogold staining of ultrathin sections. Semin Thromb Hemost (1996) 0.75
Different activation states of GP IIb/IIIa complexes in platelets. Blood Coagul Fibrinolysis (1999) 0.75
Screening for factor V Leiden and a prothrombin gene polymorphism in patients with Glanzmann's thrombasthenia. Br J Haematol (1998) 0.75
Accessibility of abciximab to megakaryocytes and endothelial cells in the bone marrow compartment: studies on a patient receiving antithrombotic therapy. Br J Haematol (1999) 0.75
[A study of platelet activation following coronary angioplasty. Effect on acute occlusion and restenosis]. Arch Mal Coeur Vaiss (1996) 0.75
Are patients with Glanzmann thrombasthenia and the Bernard-Soulier syndrome protected against atherosclerosis? Adv Exp Med Biol (2001) 0.75
A patient with autoimmune thrombocytopenic purpura demonstrating serum antibodies reactive with mouse cross-reactive idiotypes. Clin Immunol Immunopathol (1995) 0.75
Heterozygotes in the bernard-soulier syndrome do not necessarily have giant platelets or thrombocytopenia. Br J Haematol (2003) 0.75
[Clinicobiological study of 100 symptomatic patients with factor V Leiden mutation]. Rev Med Interne (2000) 0.75
[Diagnosis of Glanzmann thrombastenia in a 66-year-old patient]. Ann Biol Clin (Paris) (2001) 0.75
Mutation analysis for a patient with Glanzmann thrombasthenia who produced a landmark isoantibody to the αIIbβ3 integrin. J Thromb Haemost (2010) 0.75
[From platelet functions to therapy]. Rev Med Interne (2010) 0.75